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Abstract
Autoimmune disease refers to a systemic immune response by the body against its own healthy tissue and cells . This results in 
various non-specific and systemic inflammatory processes that evolve into more than 100 individual diseases. Numerous bio-
logical similarities exist between the different pathophysiological pathways, including biochemical cascades and inflammasome 
mediators . This paper aims to investigate whether contracting one form of autoimmune disease can lead to the development of 
polyautoimmunity and multiple autoimmune syndrome. Scientists have identified chronic levels of high stress as a contributor to 
higher levels of C-reactive protein and several immune modulating interleukins, which can lead to both autoimmune and polyau-
toimmune processes (Steptoe et al ., 2007) . Immunologists and virologists have established how viruses can lead to autoreactive 
immune activity through molecular mimicry and epitope spreading. These same processes are found in all forms of inflammation 
and may explain the connection between undiagnosed adult-onset celiac disease and multiple autoimmune syndrome . Many 
genetic pathways have been identified as drivers of both individual autoimmune conditions and specific inflammasome mediators 
that could be responsible for familial based autoimmunity and specific subtypes of multiple autoimmune syndrome. Collectively, 
these studies underlie and illustrate a direct connection between several contributors that definitively link autoimmunity with 
polyautoimmunity .
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Introduction
Autoimmunity is defined as the misdirected immune re-
sponse by an organism against its own healthy tissue and 
cells. Encompassing as many as one hundred individual 
diseases, autoimmune disease affects nearly 23 million 
Americans of all ages and has been referred to by many 
as the next frontier in the battle for longevity (NIH 2012). 
Some of the more common manifestations of autoim-
munity include Crohn’s disease, colitis, systemic lupus 
erythematosus, Sjogren’s syndrome, celiac disease and 
type 1 diabetes. The specific mechanisms and causes of 
these diseases are still the subject of investigation, some 
of which will be explored in the following discussion. It is 
widely recognized that autoimmune disease is on the rise 
across nearly all age groups and social categories (Dinse 
et al., 2020). The reason for this increase is unclear, though 
many believe that environmental conditions as well as be-
havioral factors may be to blame. 
As the general rate increases, an important question 
arises. Does contracting one form of autoimmune disease 
raise the risk of developing another? Since many symp-
toms of autoimmune disease overlap with one another, 
perhaps a connection between them exists. For instance, 
Sjogren’s, Behcet’s and celiac disease all present with aph-
thous ulcers in the mucosal lining of the oral cavity. Even 
though overlapping symptoms clutter the differentials and 
make a definitive diagnosis more elusive, these common-
alities may demonstrate a connection between the vari-
ous diseases.  In addition to overlapping symptoms, many 
autoimmune diseases share specific pro-inflammatory 
cytokines such as IL-1, IL- 6, and TNF-alpha, which trigger 
the release of inflammation markers like CRP, Fibrinogen, 
and Haptoglobin (Castro, Gourley, 2010). Another study 
found that specific CD4+ T lymphocytes responsible for 
misidentifying healthy tissue as foreign were found in 3 
separate autoimmune diseases (Christophersen et al., 
2019). Using mass cytometry and RNA sequencing, the 
CD4+ T lymphocytes were first identified in celiac pa-
tients but were later linked to Systemic lupus and mul-
tiple sclerosis. While only a correlation, the findings may 
explain why some immune modalities are more suscep-
tible to make mistakes and whether contracting one dis-
ease such as celiac raises the risk of more activity.
Since there are multiple drivers of disease, the inves-
tigation into polyautoimmunity and how its diseases are 
linked will need to focus on several factors, including the 
environment, hormones, and genetic predispositions. 
Perhaps the environment and exposure to chemicals and 
pollution are interfering with a healthy immune system? 
Maybe bacterial diseases and viruses are propelling the 
immune system to turn on itself in multiple ways? Lastly, 
can specific genes be contributing to patterns that have 
been established between specific conditions such as ce-
liac and type 1 diabetes?
Methods
The research reviewed in this article was obtained using 
several online databases and search tools, including 
Pubmed, JSTOR, and Google Scholar. Information was 
also accessed through the Touro College Libraries data-
base using EBSCO and ProQuest. 
Discussion  
Mechanisms of Autoimmunity
Before exploring the polyautoimmunity connection, it is 
important to first analyze and define the autoimmune 
response itself. Over the last several decades, scientists 
have formulated several explanations to illustrate the 
specific pathways and mediators responsible for a typical 
immune reaction in the body’s tissues. Researchers isolat-
ed and identified one such pathway using cytometry and 
RNA sequencing on tissue derived from inbred C57BL 
mice. Upon initial activation, CD4+ T cells produce cy-
tokine tumor necrosis factor (TNF), which engages its 
25
The Relationship Between Autoimmunity and Polyautoimmunity 
TNF receptor on mononuclear phagocytes (MP). This 
leads to the synthesis of pro-cytokine interleukin (IL)-1B. 
Concurrently, CD4+ cells also express membrane-bound 
Fas-Ligand (FasL), a subgroup of the tumor necrosis re-
ceptor family, which activate death receptor Fas signaling 
in nearby macrophages, leading to the induction of the 
inflammation process. This eventually results in Caspase-
8-dependent-pro-IL-1B cleavage. Caspase-8 is believed to 
regulate inflammation through the modulation of mRNA 
expression in inflammasomes (Gurung, Kanneganti, 2015). 
The researchers concluded that the inflammasome-inde-
pendent cytokine interleukin 1B was believed to be re-
sponsible for the systemic inflammation found in general 
autoimmune responses. Consequentially, when tumor 
necrosis factor receptors or Fas signaling was inhibited in 
the population, the mice were protected from cell-driven 
immunity (Jain et al., 2019). 
These cytokine interleukins (IL-1B, IL-18, IL-6) have 
been identified in further studies to be a central player 
in innate immune responses due to their interaction with 
inflammasomes. Broadly speaking, cytokine interleukins 
have been found to be present in almost every immune 
reaction. However, what makes each reaction unique and 
specific to individual tissues and organ systems is the type 
of inflammasome involved in the response (Rathinam et 
al., 2012). Inflammasomes were first discovered in 2002 as 
a prominent component of type 2 diabetes and systemic 
gout. As a type of macrophage, these inflammasomes are 
a key player in cytosolic surveillance, constantly scan-
ning the interstitial space for signs of tissue injury or 
infection. The human genome has been found to contain 
twenty-three Nod-like-receptor (NLR) nucleotide-bind-
ing and oligomerization domains (Nods), many of which 
codify and assemble into inflammasome complexes. Each 
of these different complexes interacts with and control 
for the release of cytokine interleukins in response to 
various bacterial pathogens, viruses, and even cancer 
(Rathniham et al., 2012). In a healthy individual, these spe-
cific pathways of inflammatory signaling are kept in check 
in order to respond only to the invading microorganism. 
When this process breaks down, autoimmunity develops. 
It is important to keep these unique pathways and cellu-
lar components in mind when investigating polyimmunity 
and the link between individual diseases. 
Stress and Poly-Autoimmunity
During the last several decades, significant research has 
been directed on the role that stress plays in the devel-
opment of autoimmune disease. Various forms of both 
short-and-long-term stress exacerbate already exis-
tent conditions such as rheumatoid arthritis (RA). One 
twelve-week study involving forty-one women suffering 
from RA found a significant relationship between even 
minor stress and joint pain (Zautra et al., 1997). However, 
these studies were unable to provide an association 
between chronic stress and the initial manifestation of 
diseases. Researchers focused on four common pro-in-
flammatory cytokines in patients with increased levels of 
acute stress, IL-1B, IL-6, TNF-alpha, and C reactive pro-
tein (CRP), and cortisol. One meta-analysis examined 30 
studies in order to determine the effects that stress had 
on these robust effects for higher levels of IL-1B, IL-6 
and TNF-alpha while the results for CRP were mixed 
(Steptoe et al., 2007). It is possible that these higher lev-
els of interleukin exasperated by stress leads to multi-
ple autoimmune conditions being contracted. One 2018 
study aimed to investigate the link between stress and 
developing autoimmunity. The retrospective cohort study 
followed 1,171,104 people, 106,464 of whom were diag-
nosed with a stress-related disorder. The results showed 
that the stressed patients were almost three times more 
likely (95% Cl, 9.2 per 1000) to develop some form of 
autoimmunity versus the non-stressed cohort (95% Cl, 
2.99-3.25 per 1000). In addition, patients were also more 
likely to develop multiple autoimmune conditions, espe-
cially when they did not seek any treatment for anxiety 
(Song et al., 20 Though this study did not investigate why 
stress causes autoimmune disease, the correlation clearly 
indicates that stress plays a prominent role in the de-
velopment of multiple autoimmune conditions and more 
research will be needed to establish why this occurs.
Viruses and Polyautoimmunity
There are two main hypotheses proposed to explain the 
connection between viral pathologies and autoimmuni-
ty. One coined “molecular mimicry” by Robert Fujinami 
in 2006 refers to the misrecognition of an antigen by a 
memory B-cell. The belief is that immunological mem-
ory is achieved after initial microbial and viral infection 
by a host-pathogen. Antigens from the initial infection 
stimulate humoral immunity and the production of plas-
ma cells and memory B-cells. If these antigens reappear 
during the secondary response, they will reactivate the 
plasma B-cells to proliferate and then destroy the in-
vading pathogen. If an organism’s self-antigen mimics the 
viral antigen in some way, then a secondary response is 
likely to occur against the body’s own tissues (Kim et 
al., 2007). There are three identified ways that this might 
occur. The first is when the original antigen and the 
self-antigen share identical amino acid sequences in their 
primary protein structure. A second possibility is when 
secondary and tertiary structures mimic each other, such 
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as with similarities regarding polarity, hydrogen, and di-
sulfide bonding. A third type of molecular mimicry exists 
when one antibody becomes capable of recognizing two 
or more antigens with completely different structures 
(Cunningham 2009). Researchers now believe that this 
third mechanism is the result of individual T-cells exhibit-
ing receptors for both foreign and self-antigens. When a 
foreign insult triggers the T cell, it then moves to attack 
healthy body tissue as well. This third mechanism has con-
sistently been linked to multiple autoimmune diseases or 
polyimmunity (Cusick et al., 2012). For instance, studies 
have linked Herpes simplex virus to stromal keratitis and 
type 1 diabetes, streptococcus to rheumatoid myocarditis 
and poststreptococcal autoimmune disorder, as well as 
many others (Munz et al., 2009).
Another hypothesis that explains how viruses gener-
ate autoimmune disease is that a virus induces a systemic 
and non-specific activation of the immune system that 
eventually leads to an overexcitability state and autore-
active immunopathology (Munz et al., 2009). Known as 
the “bystander activation,” this line of reasoning stems 
from the fact that, similar to stress, those already suffer-
ing from autoimmune conditions tend to fare worse with 
their symptoms whenever they are infected with a virus. 
Scientists believe that the pro-inflammatory environment 
in the body initiates a release of self-antigens from in-
fected tissue. The antigens are then mistakenly taken up 
by major histocompatibility complexes (MHC) or anti-
gen-presenting cells (APC), which then present these 
self-antigens to autoreactive T cells that have already 
migrated to the damaged tissue (Fujinami 2006). This can 
sometimes lead to a concatenation of events known as 
“epitope spreading,” where these T cells begin attacking 
other self-antigens that mimic the previous one, further 
inflaming the tissue and releasing even more self-epitopes. 
This phenomenon has been observed in multiple sclero-
sis, autoimmune encephalomyelitis and myasthenia gravis 
and has been linked to viruses such as EBV, rotavirus 
and cytomegalovirus (Smatti et al., 2019). It is important 
to note growing evidence that viruses may also play a 
protective role in preventing autoimmunity by activating 
regulatory immune responses that work to suppress in-
flammation and inhibit cytokine interleukins. In addition, 
scientists still do not know whether higher viral loads or 
compromised immune systems during the infection peri-
od, raise the risk of autoimmunity. 
This second idea regarding how bystander activation 
and molecular mimicry leads to multiple autoimmune 
syndrome (MAS) illustrates how inflammation leads to 
more inflammation. This concept may explain the essence 
of another important phenomenon. For many years, 
doctors have emphasized  the  importance of treating 
previously diagnosed autoimmune conditions and disor-
ders in order to improve a patient’s prognosis and quality 
of life. These treatments have included the use of bio-
logics, corticosteroids, dietary modifications and lifestyle 
changes. Scientists have long believed that inflammatory 
processes that are left unchecked can lead to the devel-
opment of coronary artery disease and even cancer. Now, 
researchers have discovered another important reason 
to aggressively treat these immunological processes: un-
treated autoimmunity increases the risk of developing fur-
ther autoimmune conditions. In 1999, researcher Andrea 
Ventura postulated that for individuals with celiac disease, 
the later the age of diagnosis, the greater the risk of devel-
oping a second autoimmune condition as well as cancer 
(Ventura et al., 1999). For example, those who were diag-
nosed between the ages of four and twelve had a 14% risk 
of developing another condition, while those over twenty 
years of age had a 34% risk. For each one-year increase in 
age at diagnosis, the chances for developing another dis-
ease increased by 1.1% regardless of gender or weight. In 
his study, Ventura explained that the longer the duration 
of exposure to gluten, the higher the prevalence of other 
autoimmune conditions developing. Further studies by 
other researchers revealed that 15% of untreated celiac 
patients eventually developed type 1 diabetes and that 
26% percent developed autoimmune thyroid disease such 
as Hashimoto’s thyroiditis and Graves’ disease (Lauret, 
Rodrigo, 2013). These studies were significant because 
most of these patients were asymptomatic and prior to 
that, many questioned the importance of adhering to a 
strict gluten-free diet. In a later paper published in the 
Journal of Pediatrics, Ventura advocated for the strict 
use of a gluten-free diet to reduce and even prevent the 
manifestation of secondary autoimmune activity, after he 
demonstrated that celiac patients who followed a strict 
gluten-free diet for two years were more than 50% less 
likely to develop other autoimmune conditions. (Ventura 
et al., 2000). Additionally, other studies also reported sim-
ilar findings regarding Crohn’s disease and colitis. In one 
study, patients were found to be 2.5 times more likely 
to develop a co-morbid inflammatory disease within five 
years after an initial diagnosis (Bernstien et al., 2005).
While the absolute reason for this phenomenon hasn’t 
yet been identified, many hypothesize that the prolonged 
state of inflammation, caused by high concentrations of 
glutamine and proline found in the protein fraction of 
rye, wheat, spelt and barley contribute to other diseases. 
Specifically, these residual peptides and amino acids initi-
ate a cascade of interleukins (IL-1B, IL-6 and IL-18) that 
trigger the proliferation of other inflammatory markers, 
including inflammasomes and C-reactive protein (CRP). 
Higher levels of CRP have been implicated in coronary 
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artery disease as well as rheumatoid processes. In ad-
dition, specific phenotypes of CD4+ helper T-cells that 
are activated in celiac disease are of the same subtype 
involved in some of the other conditions such as sys-
temic lupus and multiple sclerosis (Christophersen et 
al., 2019). (Though these specific T-cells comprise less 
than 2% of all the Helper T-cells in the body, they are 
disproportionately responsible for the identification of 
most self-antigen responses that take place within these 
inflammatory pathways.) This phenomenon seems to be 
related to the mechanism of molecular mimicry and dual 
T cell activation discussed earlier, which takes place in 
response to viral infections. However, in this scenario, an 
initial autoimmune condition takes the place of the virus 
and contributes to a set of circumstances where the body 
continuously mistakes healthy tissues as foreign and as 
a threat. It is clear from these studies that untreated or 
resistive autoimmune processes have a direct effect on 
the risk of further developing other forms of chronic in-
flammation which may lead to the manifestation of other 
autoimmune conditions. 
Genetics and Polyautoimmunity
Upon examination, autoimmune diseases appear to man-
ifest in clusters. Though Ventura investigated all forms 
of autoimmunity, he reported that individuals with celi-
ac were much more predisposed to developing type 1 
diabetes and thyroid disease versus ulcerative colitis or 
Addison’s disease. Rheumatoid arthritis has been linked 
to Sjogren’s syndrome, while systemic lupus erythemato-
sus has been linked to multiple sclerosis. Indeed, so specif-
ic are these clusters that investigators have now classified 
these groups into three clinical subtypes (Cojocaru et al., 
2010). Of note, each of these subtypes contain at least 
one skin condition and one connective tissue disease. 
I. Type 1 is comprised of polymyositis, thymoma, giant 
cell myocarditis and myasthenia gravis. 
II. Type 2 consists of rheumatoid arthritis, Hashimoto’s, 
scleroderma, and Sjogren’s syndrome.
III. Type 3 is the largest subgroup and includes Addison’s 
disease, type 1 diabetes, vitiligo, psoriasis, autoim-
mune hemolytic anemia, dermatitis herpetiformis, 
idiopathic thrombocytopenic purpura (ITP), Sjogren’s 
syndrome, myasthenia gravis and systemic lupus 
erythematosus.
Patients diagnosed with having more than one auto-
immune condition are said to have polyimmunity, while 
patients diagnosed with more than two are classified as 
having multiple autoimmune syndrome (MAS) type i, ii, or 
iii. These classifications are not absolute; however, they 
provide clinicians and scientists with an understanding of 
what to look out for and how to treat each patient based 
on their specific classification. Researchers have discov-
ered that families also seem to develop these illnesses as 
a group. For example, a mother may develop Addison’s 
disease while a daughter is diagnosed with lupus and a 
grandson has vitiligo (Cardenas-Roldan et al., 2013). This 
occurrence seems to confirm that in addition to the envi-
ronment, genetics play a broad and important role in the 
development of multiple autoimmune syndrome which 
will be discussed. 
Scientists employed genome-wide association study 
(GWAS), genome scans and RNA sequencing to investi-
gate common genetic etiologies that contribute to auto-
immune diseases and polyautoimmunity. They identified 
loci responsible for the human leukocyte antigen (HLA) 
region on DNA that contribute to autoimmunity.  The 
researchers also identified loci shared between the most 
common autoimmune conditions which included IL23R, 
OLIG3/TNFAIP3 and IL2RA. The study revealed that type 
1 diabetes was genetically associated with rheumatoid ar-
thritis and that Crohn’s disease was linked with ulcerative 
colitis. It also underlined how some diseases seem capa-
ble of developing without any genetic links, particularly 
systemic lupus erythematosus (SLE) and systemic sclero-
sis. This would suggest that not all forms of autoimmune 
disease are caused by genetic heritability and phenotype. 
Rather, genes play a sizable role in the broader picture of 
how autoimmunity manifests (Ramos et al., 2011). 
The Major Histocompatibility Complex (MHC) gene 
has been investigated as an important factor in autoim-
munity. Located on chromosome 6, the locus codes for 
cell surface proteins found on numerous lymphocytes 
as well as receptors found on almost every living cell in 
humans. Scientists performed a genome-wide associa-
tion study (GWAS) on the MHC gene which compares 
the allele/genotype frequency between individuals that 
have been affected by disease and those who have not. 
The study visually confirmed that the MHC locus is a 
major predicator in most autoimmune conditions (Kochi, 
2016). The most common MHC genes include HLA-A, 
HLA-B and HLA- DP/DQ/DR. Since these genes play a 
crucial role in the adaptive immune response, perhaps it 
is possible to surmise that MHC genes are involved in 
the formation of autoimmunity in general. However, this 
does not explain why one patient develops Crohn’s dis-
ease and one Hashimoto’s disease.  The development of 
a specific disease or condition can be caused by a single 
allele, yet this does not prove that a single allele can cause 
polyautoimmunity. For example, rheumatoid arthritis has 
been linked to multiple HLA-DRB1 alleles such as *01:01, 
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*04:01, *04:05 and *09:01 while Ankylosing spondylitis is 
known to be caused by the allele, HLA-B27 (Newton et 
al., 2004).
Researchers have identified a mutation in the genetic 
factor PTPN22 as an important driver of multiple auto-
immune syndromes. PTPN22 is responsible for encoding 
lymphoid-specific tyrosine phosphatase, a critical regula-
tor of T-cell receptor signaling pathways. A single nucleo-
tide missense mutation involving PTPN22 has been linked 
to rheumatoid arthritis, type-1 diabetes and systemic 
lupus erythematosus. FC receptors (FcRs) on the surface 
of immune cells recognize immune complexes comprised 
of autoantigens and autoantibodies. After the immune 
complex binds to the receptor, FcRs release Src and Syk 
family kinase which leads to antigen uptake, presentation 
and secretion of interleukins and proteins that initiate 
an immune response. Tyrosine phosphatase encoded by 
PTPN22 inhibits the release of Src and Syk kinase, there-
by regulating the FcR immune response in dendritic cells. 
In one study, patients who had a C1858T missense poly-
morphism in PTPN22, were found to have higher levels 
of Scr and Syk kinase as well as higher instances of type 
1 diabetes. In another study, bone marrow derived den-
dritic cells of wild type mice (PTPN22-/) were compared 
with dendritic cells from knockout mice with PTPN22-/-. 
The PTPN22-/- dendritic cells had higher levels of T cell 
proliferation and activity (Clarke et al., 2018).
Studies examined innate immunity to determine if 
genes responsible for the initial immune response play 
a role in autoimmune development. In innate immunity, 
macrophages and dendritic cells express toll-like recep-
tors which recognize patterns on virus antigens and then 
activate type 1 interferons responsible for immunomod-
ulatory and antiviral responses. These interferons or 
cytokines bind to receptors on white blood cells which 
activate a cascade of secondary messengers which inter-
fere with the further proliferation of the invading virus. A 
subgroup of the interferon proteins, the type 1 interferon, 
has been implicated in myositis and systemic lupus er-
ythematosus. Research demonstrated that patients with 
lupus displayed higher levels of type 1 interferons at diag-
nosis when compared with individuals without symptoms 
of disease (Padilla, Niewold, 2016). Additionally, genome 
wide association studies for systemic lupus erythematosus 
discovered multiple gene and loci sites that were directly 
linked with type 1 interferons and its associated signaling 
pathways. These included IFIH1, IRF5, IRF7, TLR7, IRAK1 
and TYK2. Other studies using GWAS identified these 
loci sites in other autoimmune conditions. For example, 
type 1 diabetes, psoriasis and Addison’s disease have been 
linked to IFIH1. Interestingly, these three diseases are all 
included in the type 3 subgroup of multiple autoimmune 
syndrome (MAS) described earlier. Similarly, the IRF5 loci 
was correlated with primary biliary cirrhosis, Crohn’s dis-
ease, colitis and rheumatoid arthritis. 
Patients with lupus who presented with the IRF5 risk 
haplotype also had higher levels of signal transducer and 
activator of transcription 4 (STAT4). STAT4 is a tran-
scription factor involved in the differentiation of T-helper 
1 (Th1) cells. Researchers believe that increased levels 
of STAT4 may increase the activity and proliferation of 
these T cells leading to autoimmunity (Kochi Yuta, 2016). 
STAT4 is activated by type 1 interferons and is respon-
sible for the synthesis of IFN-y, another interferon type. 
This discovery highlights how one gene factor can drive 
multiple different components that lead to disease. IRF5 
produces excess interferons that may exacerbate an au-
toimmune response in the innate immune system, while 
simultaneously activating STAT4 which is involved in 
adaptive immunity. Also noted in the literature, was that 
lupus patients who presented with the PTPN22 muta-
tion discussed had reduced levels of TLR7 induced type 
1 interferons, possibly indicating heterogeneity of disease 
expression (Wang et al., 2015). These studies clearly in-
dicate that genetics play a role in both innate as well as 
adaptive immunity and that there are several overlapping 
genetic variances that contribute to the manifestation of 
multiple autoimmune conditions. 
Studies performed using genome-wide association 
studies (GWAS) identified and linked individual genes with 
specific autoimmune conditions. Researchers investigated 
whether one gene can be responsible for general autoim-
munity encompassing a broad number of non-specific au-
toimmune conditions. One study focused on the ITGAM 
gene, a genetic region responsible for the alpha-chain 
subunits found in a cell surface receptor of neutrophils 
and monocytes named Integrin-aMB2. A variant at exon 
3 (rs1143679) within the ITGAM gene was thought to 
up-regulate the binding capacity of Integrin-amB2 which 
would increase the susceptibility to multiple autoimmune 
syndromes. However, SNP genotyping, statistical and me-
ta-analysis of the gene region confirmed that there was 
no significant association between systemic sclerosis, 
scleroderma, rheumatoid arthritis and the ITGAM gene. 
Only systemic lupus erythematosus was found to be 
directly correlated with the re1143679 mutation found 
in the population (Anaya et al., 2011). Still, researchers 
have identified a general autoimmune contributor using 
GWAS. As previously discussed, pro-inflammatory cy-
tokines play a major role in the development of auto-
immune conditions. Researchers studying the origins of 
celiac disease discovered an association between celiac 
29
The Relationship Between Autoimmunity and Polyautoimmunity 
disease and the receptor for Interleukin-23 (IL-23). Two 
subunits (p40 and p19) within IL-23 are found within the 
IL-12 and IL-1B receptors as well. (IL-12 receptors are 
composed of p40 and p35 heterodimers while IL-1B con-
tains p19 dimers.) Additionally, the p19 (IL23R) subunit 
on IL-23 is located just 3’downstream to the p40 subunit 
(12RB1) on IL-12. This highlights just one of the many 
connections between cytokinetic interleukins and auto-
immune disease. Indeed, the IL-23 receptor has also been 
linked to psoriasis, rheumatoid arthritis, Crohn’s disease 
and multiple sclerosis (Tang et al., 2012). Other diseases 
have been linked to specific interleukins as well. IL-2 and 
IL-2R were found to have a direct connection with pso-
riasis, Gaucher disease, rheumatoid arthritis and type 1 
diabetes while IL-21 was linked with multiple sclerosis 
as well as inflammatory bowel disease. The studies did 
not investigate or confirm whether contracting one of 
the autoimmune conditions raised the risk of developing 
another. However, it seems plausible that if genetic and 
environmental conditions caused one disease, they could 
lead to a second one. 
Researchers at the Benaroya Research institute at-
tempted to map the many genetic connections between 
each autoimmune disease in order to determine how 
one may lead to the other. They began by investigating 
why patients with Down syndrome are 15-100 times 
more likely to develop some form of autoimmunity, many 
of whom develop polyautoimmunity as well. Additionally, 
these disorders are varied, affecting both endocrine and 
non-endocrine systems. Diseases commonly seen include 
thyroid disease, type 1 diabetes, scleroderma, Sjogren’s 
syndrome, systemic lupus erythematosus, autoimmune 
hemolytic anemia and celiac disease. A biorepository of 
blood and tissue samples was established using tissue 
extracted from the Down syndrome population as well 
as from their healthy siblings. Since Down syndrome is 
caused by trisomy 21 (HSA21) and is genetic in nature, 
researchers focused on the genetic drivers in these pa-
tient’s immune responses and composition. They also in-
vestigated whether one gene could be the driving force 
behind all these illnesses. The data identified a gene called 
dual-specificity tyrosine-(Y)-phosphorylation-regulated 
kinase 1A (DYRK1A) as a possible driver of autoimmuni-
ty. Previously, this gene was linked to the cognitive decline 
and neuro-developmental conditions found in most pa-
tients with Down syndrome (Feki, Hibaoui, 2018). Patients 
with Down syndrome express an excessive amount of 
DYRK1A as a result of the extra chromosome HSA21, 
leading to a buildup of proteins that lead to memory 
deficit and motor abnormalities. Scientists hypothesized 
that DYRK1A produces excess proteins that prevent the 
body from shutting off unnecessary inflammatory im-
mune responses leading to autoimmune disease. 
In a separate study, researchers worked to identify sub-
stances that could increase the number of Treg cells, white 
blood cells that suppress other immune cells, in order 
to prevent autoimmunity. The scientists believed that by 
increasing Treg cells while maintaining or even inhibiting T 
helper cells, a novel therapeutic approach to autoimmu-
nity could be found. Using Similarity Ensemble Approach 
(SEA) and chemoinformatic methods involving 3,100 sub-
stances, the team isolated a chemical called B-carboline 
alkaloid harmine and discovered its ability to reduce 
autoimmune activity in induced inflammatory reactions 
in vitro. Further studies demonstrated that harmine acts 
in part by inhibiting DRYK1A which led to differentia-
tion of Treg cells. More importantly, when DRYK1 was 
inhibited, T1 helper cell and T17 helper cell differentiation 
remained constant or was reduced. The team then tested 
harmine’s impact on Treg and T helper cells in vivo, using 
three separate subtypes of inflammation; type 1 diabetes, 
colitis and asthma. The three inflammatory diseases were 
chosen for their T cell properties, diverse genetic back-
grounds and distinct tissue types. When Foxp3 mice were 
induced with type 1 diabetes, the mice developed diabe-
tes approximately 10 days after injection. When the mice 
were induced under TregHarmine conditions, onset was 
delayed by a minimum of seven days. Next, when mice 
with ulcerative colitis were injected with TregHarmine, 
mucosal inflammation in the intestines was significantly 
reduced. Finally, researchers induced Foxp3 mice with 
airway inflammation using intratracheally administered 
ovalbumin. When these mice were treated with Harmine, 
a significant suppression of inflammation was noted (Kohr 
et al. 2015). These findings benefit the hypothesis that 
the overexpression of DYRK1A in patients with Down 
Figure 1 illustrates the various linkages between differentially 
expressed genes and five common autoimmune conditions.
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syndrome may contribute directly to the development 
of autoimmune disease by increasing differentiation of T1 
helper cells, while simultaneously preventing the expres-
sion of anti-inflammatory Treg cells. This might explain the 
broad spectrum of disorders seen in Down syndrome 
since helper T cells and Treg cells are involved in almost 
all autoimmune disorders. Additionally, as a DYRK1A in-
hibitor, B-carboline alkaloid harmine should be further in-
vestigated as a therapeutic for Down syndrome patients 
with autoimmune conditions. Another potentially im-
portant question is whether inhibiting DYRK1A can also 
decrease some of the neurological symptoms seen with 
Down syndrome cases, since DYRK1A has also been as-
sociated with the mental retardation and cognitive delay 
that is prevalent in these cases. 
GWAS was able to identify and establish a substan-
tial link between genetics and autoimmune disease. In 
addition, many of these genes have also been linked to 
multiple autoimmune syndromes and illnesses. However, 
just because an individual is genetically predisposed does 
not guarantee the development of one or several auto-
immune conditions. Epigenetically, these genes can be reg-
ulated due to several mechanisms and several epigenetic 
processes have been linked to autoimmune disease. These 
include DNA methylation, post-translational histone pro-
tein modifications, chromatin remodeling and RNA regu-
lation of gene expression. DNA methylation involves the 
addition of a methyl group to carbon 5 on the cytosine 
molecule of cytosine phosphate-guanosine resulting in 
5-methylcytosine. The methyl groups occupy the major 
groove of DNA, thereby silencing the gene by blocking 
proteins and transcription factors from forming transcrip-
tion complexes on the DNA helix. DNA demethylation 
can also occur through the enzyme-catalyzed removal of 
cytosine methyl groups. Researchers studying systemic 
lupus erythematosus were able to identify specific epi-
genetic processes by focusing on the development of 
peripheral blood mononuclear immune cells of patients 
affected with lupus and then comparing them to their 
identical monozygotic twin siblings. The results identified 
approximately 50 instances of DNA hypomethylation in 
the gene regions of the lupus patients. Absolute cause for 
the hypomethylation was not identified, although possi-
bilities that were mentioned include UV exposure, age, 
viruses and environmental stress (Surace and Hedrich, 
2019). More research is needed to investigate DNA 
methylation in other autoimmune conditions as well as 
other immune cell types. 
Histone modifications occur via covalent posttransla-
tional alterations of amino acids at the N-terminal end 
of histone proteins. These changes include adding or 
removing a phosphate, acetyl and methyl group that trans-
forms the chromatin structure, making the DNA unavail-
able for transcription. A similar concept called chromatin 
remodeling occurs when ATP-powered protein complex-
es attached to chromatin, alter, remove or transfer the 
nucleosome to another part of a chromosome. Scientists 
explored the genetic links of Cryopyrin-associated peri-
odic syndrome (CAPS), a rare autoimmune disease that 
consists of three phenotypic processes: Muckle-Wells 
syndrome, neonatal-onset multisystem inflammatory 
disease and familial cold autoinflammatory syndrome. 
The results of one study revealed a down-regulation of 
numerous genes which included the histone proteins 
SUMO1 and HIST2H2AC as well as histone deacetylase 
enzymes HDAC1/2 (Surace and Hedrich, 2019). However, 
a second study involving CAPS demonstrated excessive 
levels of DNA demethylation which results in an epigen-
etic up-regulation of genes as the driver of the inflamma-
tory process (Tormo et al., 2017). These studies illustrate 
the immense complexity of histone modifications and 
epigenetics in general. Though the two studies appear to 
contradict each other, it is highly plausible that epigenetic 
events not only vary considerably between diseases but 
even between individuals as well. Still, these studies were 
limited in scope and design and more research is needed 
to fully understand the epigenetic connection to CAPS 
and how different events drive the genetic expression of 
inflammatory processes. 
RNA regulation involves the repression of gene expres-
sion through long and short noncoding RNAs (ncRNA). 
Long ncRNA’s are silent and lack an extended open 
reading frame required for translation. Short ncRNA’s 
include micro-RNAs (miRNAs), short interfering RNAs 
(siRNAs) and piwi-interacting RNAs (piRNAs). Micro-
RNAs are transcribed as precursor molecules 80-100 
bases long and after hydrolytic cleavage are processed to 
contain 20-23 bases. The shortened span allows them to 
interfere with DNA methyltransferase thereby inhibiting 
DNA methylation. During the CAPS studies mentioned 
earlier, researchers were able to identify a direct asso-
ciation between miRNA and upregulation of the STAT4 
gene responsible for CD4+ T helper 1 cell proliferation. 
In addition, STAT3 and STAT1 were also upregulated, re-
sulting in increased cytokinetic activity, specifically IL-6 
and IL-17A (Surace and Hedrich, 2019). Since epigenetics 
contain many factors, it is difficult to determine the exact 
role it plays in polyautoimmune disease. However, epigen-
etic processes have been identified in some of the uni-
versal genes described earlier. For example, the ITGAM 
gene that contributes to multiple autoimmune diseases 
contains approximately 40 sites of DNA methylation and 
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histone modifications. Though scientists are unsure of 
the specific effects and links for these sites, many roles 
and possibilities exist. As science continues to explore 
the complex concept of gene expression and epigene-
tic factors, researchers will surely uncover many other 
associations between multiple autoimmune diseases and 
epigenetics. 
Conclusion
Research has identified several risk factors for developing 
polyautoimmunity. It is clear from the data that the pres-
ence of one autoimmune disease raises the risk for devel-
oping further illnesses. Chronic and acute forms of stress 
facilitate autoimmune processes by raising inflammatory 
markers in the bloodstream. Though viruses and bacteria 
typically prime the adaptive immune system for future 
responses, molecular mimicry, bystander activation and 
epitope spreading can direct a vulnerable immune system 
to turn on itself. Furthermore, untreated and protracted 
forms of inflammation might lead to autoimmune disease 
through bystander activation or similar forms of immune 
dysfunction. Genetic processes involving interleukins 
and inflammasome signaling, regulate the many compo-
nents responsible for managing a healthy immune system. 
Mutations and hereditary factors involving these genes 
can directly contribute to multiple autoimmune diseases. 
Lastly, epigenetic elements driven by DNA methylation 
and hypomethylation of cytosine bases as well histone 
modification and RNA regulation can lead to the develop-
ment of multiple autoimmune diseases, though the exact 
connection is not yet fully understood. The data does 
not establish absolute causation of any one contributing 
factor for developing polyautoimmunity; however, each 
additional variable enhances the risk over time. Patients 
who are genetically predisposed to autoimmune disease 
and are chronically stressed or have contracted multiple 
viruses in their lifetime,  have a significant risk of develop-
ing an autoimmune disease. If inflammation levels of the 
initial disease are not managed, patients face an increased 
risk of developing another condition. It is important for 
physicians and healthcare professionals to be aware of 
their patient’s genetic profile, susceptibility and history to 
determine the probability of further autoimmune devel-
opment. Communication among the healthcare team is 
essential since patients may have multiple doctors treat-
ing several conditions, each without knowledge of the 
patient’s complete history. Finally, through more research 
into the causes and associations of polyautoimmunity and 
multiple autoimmune syndrome, doctors will be able to 
better diagnose, treat and eventually prevent this abstruse 
and perplexing condition. 
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